Tekla Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q4
Sell
-29,500
Closed -$2.37M 136
2015
Q3
$2.37M Buy
+29,500
New +$3.28M 0.09% 138
2015
Q2
Sell
-54,300
Closed -$5.67M 119
2015
Q1
$5.67M Buy
+54,300
New +$5.5M 0.22% 75

Other funds holding ALNY

Tekla Capital Management's ALNY Position: Q2 2023 in Review

Tekla Capital Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2023 at 143,214 shares worth $27.2M. The position accounts for 1.06% of the portfolio, ranked #25.

Tekla Capital Management first reported a position in ALNY in Q3 2013 and has held it in 40 quarters since. The position peaked at $35.8M in Q3 2021. 477 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

  • Tekla Capital Management held 143,214 shares of Alnylam Pharmaceuticals worth $27.2M as of Q2 2023.
  • Tekla Capital Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2023.
  • Alnylam Pharmaceuticals made up 1.06% of Tekla Capital Management's portfolio in Q2 2023, its #25 holding.
  • Tekla Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 40 quarters since.
  • Tekla Capital Management's Alnylam Pharmaceuticals position peaked at $35.8M in Q3 2021.
  • 477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.